A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Active, not recruiting · NCT05787587 · Registry updated 2026-07-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasms by Site, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, breast cancer, breast disorder, breast neoplasm, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, intellectual disability, X-linked, with or without seizures, ARX-related, intestinal disorder, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, prostate cancer, prostate disorder, rectal disorder, skin disorder, uterine disorder | Active, not recruiting | Phase 1 | 2026-07-13 | NCT05787587 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| IDEAYA Biosciences | 12 |
| Merck Sharp & Dohme LLC | 650 |
27 results · Page 1 of 2
Research sites
Swipe the table sideways for more columns.